These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 34634770)
21. Ketoconazole 2 percent cream in the treatment of tinea pedis, tinea cruris, and tinea corporis. Lester M Cutis; 1995 Mar; 55(3):181-3. PubMed ID: 7634851 [TBL] [Abstract][Full Text] [Related]
22. A comparison of itraconazole and griseofulvin in the treatment of tinea corporis and tinea cruris: a double-blind study. Panagiotidou D; Kousidou T; Chaidemenos G; Karakatsanis G; Kalogeropoulou A; Teknetzis A; Chatzopoulou E; Michailidis D J Int Med Res; 1992 Sep; 20(5):392-400. PubMed ID: 1333423 [TBL] [Abstract][Full Text] [Related]
23. A new mutation in the SQLE gene of Trichophyton mentagrophytes associated to terbinafine resistance in a couple with disseminated tinea corporis. Hsieh A; Quenan S; Riat A; Toutous-Trellu L; Fontao L J Mycol Med; 2019 Dec; 29(4):352-355. PubMed ID: 31611164 [TBL] [Abstract][Full Text] [Related]
24. [Clinical study of itraconazole for the treatment of Tinea cruris, Tinea corporis and Tinea pedis interdigital]. Zaitz C; Ruiz LR; Drullis EM; Gurfinkel P; Ciarnuto MA Rev Inst Med Trop Sao Paulo; 1990; 32(4):299-303. PubMed ID: 1966257 [TBL] [Abstract][Full Text] [Related]
25. Itraconazole compared with griseofulvin in the treatment of tinea corporis/cruris and tinea pedis/manus: an interpretation of the clinical results of all completed double-blind studies with respect to the pharmacokinetic profile. Lachapelle JM; De Doncker P; Tennstedt D; Cauwenbergh G; Janssen PA Dermatology; 1992; 184(1):45-50. PubMed ID: 1313717 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Terbinafine Hydrochloride 1% Cream vs. Sertaconazole Nitrate 2% Cream in Tinea Corporis and Tinea Cruris: A Comparative Therapeutic Trial. Choudhary S; Bisati S; Singh A; Koley S Indian J Dermatol; 2013 Nov; 58(6):457-60. PubMed ID: 24249898 [TBL] [Abstract][Full Text] [Related]
27. Predicting a therapeutic cut-off serum level of itraconazole in recalcitrant tinea corporis and cruris-A prospective trial. Khurana A; Agarwal A; Singh A; Sardana K; Ghadlinge M; Agrawal D; Panesar S; Sethia K; Chowdhary A Mycoses; 2021 Dec; 64(12):1480-1488. PubMed ID: 34532888 [TBL] [Abstract][Full Text] [Related]
28. Oral treatment of tinea corporis and tinea cruris with terbinafine and griseofulvin: a randomized double blind comparative study. Voravutinon V J Med Assoc Thai; 1993 Jul; 76(7):388-93. PubMed ID: 8089640 [TBL] [Abstract][Full Text] [Related]
29. The use of itraconazole to treat cutaneous fungal infections in children. Gupta AK; Nolting S; de Prost Y; Delescluse J; Degreef H; Theissen U; Wallace R; Marynissen G; De Doncker P Dermatology; 1999; 199(3):248-52. PubMed ID: 10592406 [TBL] [Abstract][Full Text] [Related]
30. Current Trends of Using Systemic Antifungal Drugs and their Comparative Efficacy in Tinea Corporis and Tinea Cruris in Outpatient Department of Dermatology in a Tertiary Level Hospital. Sultana T; Saha SK; Hossain M; Ajmeri S; Sarker M; Sultana M; Nandi AK; Das PK Mymensingh Med J; 2018 Jan; 27(1):52-56. PubMed ID: 29459592 [TBL] [Abstract][Full Text] [Related]
31. End of the road for terbinafine? Results of a pragmatic prospective cohort study of 500 patients. Singh S; Shukla P Indian J Dermatol Venereol Leprol; 2018; 84(5):554-557. PubMed ID: 29893296 [TBL] [Abstract][Full Text] [Related]
32. Treatment recalcitrant cases of tinea corporis/cruris caused by T. mentagrophytes - interdigitale complex with mutations in ERG11 ERG 3, ERG4, MDR1 MFS genes & SQLE and their potential implications. Bhattacharyya A; Sadhasivam S; Sinha M; Gupta S; Saini S; Singh H; Khurana A; Sachdeva S; Sardana K; Ghosh S Int J Dermatol; 2023 May; 62(5):637-648. PubMed ID: 36929499 [TBL] [Abstract][Full Text] [Related]
33. Clinico-Mycological Profile of Treatment-Naïve, Chronic, Recurrent and Steroid-Modified Dermatophytosis at a Tertiary Care Centre in Eastern India: An Institution-Based Cross-SectionalStudy. Saha I; Podder I; Chowdhury SN; Bhattacharya S Indian Dermatol Online J; 2021; 12(5):714-721. PubMed ID: 34667758 [TBL] [Abstract][Full Text] [Related]
34. Once-weekly oral doses of fluconazole 150 mg in the treatment of tinea corporis/cruris and cutaneous candidiasis. Suchil P; Gei FM; Robles M; Perera-Ramírez A; Welsh O; Male O Clin Exp Dermatol; 1992 Nov; 17(6):397-401. PubMed ID: 1486705 [TBL] [Abstract][Full Text] [Related]
35. Clinical experience with short schedules of itraconazole in the treatment of tinea corporis and/or tinea cruris. Parent D; Decroix J; Heenen M Dermatology; 1994; 189(4):378-81. PubMed ID: 7873824 [TBL] [Abstract][Full Text] [Related]
36. Double-blind comparison of itraconazole with griseofulvin in the treatment of tinea corporis and tinea cruris. Bourlond A; Lachapelle JM; Aussems J; Boyden B; Campaert H; Conincx S; Decroix J; Geeraerts C; Ghekiere L; Morias J Int J Dermatol; 1989; 28(6):410-2. PubMed ID: 2548967 [TBL] [Abstract][Full Text] [Related]
37. Abbreviated oral itraconazole therapy for tinea corporis and tinea cruris. Sanmano B; Hiruma M; Mizoguchi M; Ogawa H Mycoses; 2003 Sep; 46(8):316-21. PubMed ID: 12950901 [TBL] [Abstract][Full Text] [Related]
38. Molecular Characterization and In Vitro Antifungal Susceptibility of 316 Clinical Isolates of Dermatophytes in Iran. Ansari S; Hedayati MT; Zomorodian K; Pakshir K; Badali H; Rafiei A; Ravandeh M; Seyedmousavi S Mycopathologia; 2016 Feb; 181(1-2):89-95. PubMed ID: 26369643 [TBL] [Abstract][Full Text] [Related]
39. Antifungal drug susceptibility profile of clinically important dermatophytes and determination of point mutations in terbinafine-resistant isolates. Salehi Z; Shams-Ghahfarokhi M; Razzaghi-Abyaneh M Eur J Clin Microbiol Infect Dis; 2018 Oct; 37(10):1841-1846. PubMed ID: 29980898 [TBL] [Abstract][Full Text] [Related]
40. Importance of mycological confirmation of clinically suspected cases of tinea corporis, tinea pedis and tinea cruris. Omar AA J Egypt Public Health Assoc; 2004; 79(1-2):43-58. PubMed ID: 16916049 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]